InformationWeek puts Roche Diagnostics on Top 500 innovative tech users list

Indianapolis—InformationWeek rankedRoche Diagnostics as one of the magazine’s top 500 innovative users of technology, an honor bestowed to only a handful of companies in the biotech and pharmaceutical industry.

Roche Diagnostics, which ranked No. 231, in the 2007 report, outperformed others in business-process efficiencies through increased automation, improved data integration, re-engineered applications and centralized control of IT operations.

“We are honored to be recognized for the third year by InformationWeek,” said Kurt Seiler, Vice President of Information Technology at Roche Diagnostics North America. “Our team has implemented key business-technology strategies that InformationWeek considers to show bottom-line efficiency and innovation.”

In its award submission, Roche pointed to the development of the cobas 6000® analyzer series as an example of the company’s innovative use of technology. The cobas 6000 analyzer series meets the changing needs of mid-volume laboratories by integrating clinical chemistry and immunoassay platforms, delivering up to 95 percent of a mid-volume laboratory’s typical testing needs.

For nearly 20 years, InformationWeek 500 has tracked and listed technology practices of the nation’s most innovative companies, including evaluation of technology deployment, IT budgets, business-technology infrastructure and IT strategies.

InformationWeek 500 is unique among corporate rankings, as it spotlights the power of innovation in information technology by measuring and celebrating accomplishments, rather than simply identifying the biggest IT spenders. To be eligible for ranking on this year’s list, Roche Diagnostics’ North American Information Technology Department was assessed on overall strategy and tactics, basic IT information and innovation essays. The six areas of focus included: increasing efficiency and productivity; customer and IT risk management; globalization; IT spending; technologies deployed; and vertical industry snapshots for more than 21 specific industries.

About Roche and the Roche Diagnostics Division

Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is a world leader in diagnostics, the leading supplier of drugs for cancer and transplantation and a market leader in virology. In 2006, sales by the Pharmaceuticals Division totaled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche employs roughly 75,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Roche’s Diagnostics Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide. For further information, please visit our U.S. Web site at www.roche-diagnostics.us.

All trademarks used or mentioned in this release are legally protected by law.

For further information please contact:

Lori McLaughlin

Corporate Communications

Roche Diagnostics Corporation

Indianapolis, Ind.

317.521.3112

lori.mclaughlin@roche.com